{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:42:54Z","timestamp":1784544174484,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio \u2018end-game\u2019 strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a\u00a0pentavalent vaccine\u00a0with whole-cell pertussis component (wP) plus IPV\/OPV vaccines to a scheme with a\u00a0hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim\u00ae) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00\u2009=\u2009$Ch 666.26).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12913-020-05115-7","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T19:02:47Z","timestamp":1586458967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine"],"prefix":"10.1186","volume":"20","author":[{"given":"Ignacio","family":"Olivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Dibarboure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Mieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n P.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Guillermo L\u00f3pez","family":"Yescas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"5115_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-7185-2_1","volume":"697","author":"DE Bloom","year":"2011","unstructured":"Bloom DE. The value of vaccination. Adv Exp Med Biol. 2011;697:1\u20138.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"5115_CR2","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2214-109X(13)70170-0","volume":"2","author":"T Barnighausen","year":"2014","unstructured":"Barnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, et al. Reassessing the value of vaccines. Lancet Glob Health. 2014;2(5):e251\u20132.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"5115_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1377\/hlthaff.2011.0381","volume":"30","author":"S Ozawa","year":"2011","unstructured":"Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, Walker DG, Levine OS. During the 'decade of vaccines,\u2019 the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood). 2011;30(6):1010\u201320.","journal-title":"Health Aff (Millwood)"},{"key":"5115_CR4","unstructured":"World Health Organization: Poliomyelitis. 2019. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis. Accessed 23 March 2020."},{"key":"5115_CR5","unstructured":"Centers for Disease Control and Prevention. Poliomyelitis In Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed: The Pink Book; 2015. https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/polio.html. Accessed 23 March 2020."},{"key":"5115_CR6","doi-asserted-by":"crossref","unstructured":"Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Vertefeuille JF, Wassilak SGF. Progress toward polio eradication - worldwide, January 2017-March 2019. MMWR Morb Mortal Wkly Rep. 2019;68(20):458\u201362.","DOI":"10.15585\/mmwr.mm6820a3"},{"issue":"6","key":"5115_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s00415-016-8108-1","volume":"263","author":"NM Nielsen","year":"2016","unstructured":"Nielsen NM, Kay L, Wanscher B, Ibsen R, Kjellberg J, Jennum P. Long-term socio-economic consequences and health care costs of poliomyelitis: a historical cohort study involving 3606 polio patients. J Neurol. 2016;263(6):1120\u20138.","journal-title":"J Neurol"},{"key":"5115_CR8","unstructured":"World Health Organization. Polio vaccines and routine polio immunization in the preeradication era. 2010. http:\/\/www.who.int\/immunization\/sage\/WHO_position_paper_on_polio_vaccines__Draft_2_March_2010.pdf. Accessed 23 March 2020."},{"key":"5115_CR9","unstructured":"World Health Organization. Polio vaccines position paper. 2016. https:\/\/www.who.int\/immunization\/policy\/position_papers\/polio\/en\/. Accessed 23 March 2020."},{"issue":"3","key":"5115_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1017\/S0950268816002569","volume":"145","author":"PL Lopalco","year":"2017","unstructured":"Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413\u20139.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"5115_CR11","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.1093\/infdis\/jiu222","volume":"210","author":"RW Sutter","year":"2014","unstructured":"Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434\u20138.","journal-title":"J Infect Dis"},{"issue":"9","key":"5115_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJMp1808903","volume":"379","author":"MA Pallansch","year":"2018","unstructured":"Pallansch MA. Ending use of Oral poliovirus vaccine - a difficult move in the polio endgame. N Engl J Med. 2018;379(9):801\u20133.","journal-title":"N Engl J Med"},{"key":"5115_CR13","unstructured":"Communicable Disease Center. Poliomyelitis surveillance. 1962. https:\/\/stacks.cdc.gov\/view\/cdc\/43716\/cdc_43716_DS1.pdf. Accessed 23 March 2020."},{"key":"5115_CR14","unstructured":"Ministerio de Salud Chile. Poliomielitis. 2015. http:\/\/www.minsal.cl\/poliomielitis\/. Accessed 23 March 2020."},{"key":"5115_CR15","unstructured":"Global Polio Eradication Initiative. Introduction of inactivated polio vaccine (IPV) in routine immunizations. 2014. http:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/inactivated_polio_vaccine\/ipv_operational_manual.pdf. Accessed 23 March 2020."},{"key":"5115_CR16","unstructured":"World Health Organization. The Polio Endgame Strategy 2019-2023: Eradication, Integration, Containment and Certification. 2019. http:\/\/polioeradication.org\/who-we-are\/polio-endgame-strategy-2019-2023\/. Accessed 23 March 2020."},{"issue":"4","key":"5115_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/14712598.2013.774368","volume":"13","author":"MC Nunes","year":"2013","unstructured":"Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013;13(4):575\u201393.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"5115_CR18","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","volume":"11","author":"K Maman","year":"2015","unstructured":"Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132\u201341.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"5115_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","volume":"26","author":"GS Marshall","year":"2007","unstructured":"Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496\u2013500.","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"5115_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","volume":"25","author":"H Kalies","year":"2006","unstructured":"Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507\u201312.","journal-title":"Pediatr Infect Dis J"},{"issue":"1 Suppl","key":"5115_CR21","first-page":"S6","volume":"9","author":"D Dodd","year":"2003","unstructured":"Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6\u201312.","journal-title":"Am J Manag Care"},{"issue":"5","key":"5115_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pedhc.2007.09.004","volume":"22","author":"MB Koslap-Petraco","year":"2008","unstructured":"Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22(5):300\u20139.","journal-title":"J Pediatr Health Care"},{"key":"5115_CR23","volume-title":"Calendario de vacunaci\u00f3n","author":"Ministerio de Salud deChile","year":"2018","unstructured":"Ministerio de Salud deChile. Calendario de vacunaci\u00f3n. 2018. https:\/\/vacunas.minsal.cl\/calendario-de-vacunacion-2018\/. Accessed 7 January 2019."},{"key":"5115_CR24","volume-title":"Calendario de Vacunaci\u00f3n 2019","author":"Ministerio de Salud deChile","year":"2019","unstructured":"Ministerio de Salud deChile. Calendario de Vacunaci\u00f3n 2019. 2019. https:\/\/vacunas.minsal.cl\/calendario-de-vacunacion-2019\/. Accessed 7 January 2019."},{"issue":"8","key":"5115_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jval.2016.04.014","volume":"19","author":"A Glassman","year":"2016","unstructured":"Glassman A, Canon O, Silverman R. How to get cost-effectiveness analysis right? The case of vaccine economics in Latin America. Value Health. 2016;19(8):913\u201320.","journal-title":"Value Health"},{"key":"5115_CR26","unstructured":"Pan American Health Organization. Promotion of evidence-based decision making for the introduction of new vaccines. 2018. https:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=13239&Itemid=841. Accessed 23 March 2020."},{"key":"5115_CR27","unstructured":"Instituto Nacional de Estad\u00edsticas ChiIe. Proyecciones de poblaci\u00f3n. Proyecci\u00f3n de poblaci\u00f3n 2002-2020. 2017. https:\/\/www.ine.cl\/estadisticas\/sociales\/demografia-y-vitales\/proyecciones-de-poblacion. Accessed 12 May 2017."},{"key":"5115_CR28","volume-title":"Programa Nacional de Inmunizaciones","author":"Ministerio de Salud de Chile","year":"2017","unstructured":"Ministerio de Salud de Chile. Programa Nacional de Inmunizaciones. 2017. http:\/\/www.minsal.cl\/programa-nacional-de-inmunizaciones\/. Accessed 22 May 2017."},{"key":"5115_CR29","unstructured":"World Health Organization. WHO\/UNICEF coverage estimates for 1980\u20132015, as of 15 July 2016. 2016. http:\/\/www.who.int\/immunization\/monitoring_surveillance\/routine\/coverage\/en\/index4.html. Accessed 23 March 2020."},{"issue":"3 Pt 2","key":"5115_CR30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1542\/peds.96.3.557","volume":"96","author":"MD Decker","year":"1995","unstructured":"Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96(3 Pt 2):557\u201366.","journal-title":"Pediatrics"},{"issue":"RR-7","key":"5115_CR31","first-page":"1","volume":"46","author":"Centres for Disease Control and Prevention","year":"1997","unstructured":"Centres for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1\u201325.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"5115_CR32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1542\/peds.68.5.650","volume":"68","author":"CL Cody","year":"1981","unstructured":"Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650\u201360.","journal-title":"Pediatrics"},{"issue":"32","key":"5115_CR33","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1016\/j.vaccine.2015.06.030","volume":"33","author":"I De Coster","year":"2015","unstructured":"De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976\u201382.","journal-title":"Vaccine."},{"key":"5115_CR34","volume-title":"Comprehensive medical consultation, Medium Complexity Hospital, Equivalent Emergency Service","author":"MAI Arancel","year":"2018","unstructured":"Arancel MAI. MINSAL Chile. In: Comprehensive medical consultation, Medium Complexity Hospital, Equivalent Emergency Service; 2018."},{"key":"5115_CR35","volume-title":"Hospitalization in Pediatric Intensive Care. 1.5 days, considering bed day price plus average attention involved (extrapolated from an influenza study)","author":"MAI Arancel","year":"2018","unstructured":"Arancel MAI. MINSAL Chile. In: Hospitalization in Pediatric Intensive Care. 1.5 days, considering bed day price plus average attention involved (extrapolated from an influenza study); 2018."},{"key":"5115_CR36","volume-title":"Central supply of the National System of health services (CENABAST)","author":"CENABAST","year":"2018","unstructured":"CENABAST. Central supply of the National System of health services (CENABAST). Chile: Ministry of Health; 2018."},{"key":"5115_CR37","unstructured":"Pan American Health Organization. Revolving fund prices. 2017.https:\/\/www.paho.org\/hq\/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es. Accessed 20 April 2017."},{"key":"5115_CR38","unstructured":"Banco Central de Chile. Paridades y Tipos de cambio. 2017. https:\/\/si3.bcentral.cl\/estadisticas\/Principal1\/enlaces\/excel\/EMF\/Excel_DEMF_EC_Paridades.html. Accessed 23 March 2020."},{"issue":"2","key":"5115_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10198-003-0216-z","volume":"5","author":"F Fagnani","year":"2004","unstructured":"Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur J Health Econ. 2004;5(2):143\u20139.","journal-title":"Eur J Health Econ"},{"key":"5115_CR40","doi-asserted-by":"crossref","unstructured":"Mascare\u00f1as A, Salinas J, Tasset-Tisseau A, Mascarenas C, Khan MM. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health. 2005;119(6):542\u20139.","DOI":"10.1016\/j.puhe.2004.08.020"},{"key":"5115_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ijid.2014.03.1307","volume":"21S","author":"K Mogale","year":"2014","unstructured":"Mogale K, Burnett RJ, Olivier D, Mphahlele J. Economic assessment of implementing Hexaxim\u00ae vaccine within the south African expanded Programme on immunisation (EPI-SA). Int J Infect Dis. 2014;21S:430.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"5115_CR42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S0950268812003093","volume":"142","author":"DW Jackson","year":"2014","unstructured":"Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect. 2014;142(4):672\u201384.","journal-title":"Epidemiol Infect"},{"issue":"12","key":"5115_CR43","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/infdis\/jiu030","volume":"209","author":"WE Smallridge","year":"2014","unstructured":"Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis. 2014;209(12):1981\u20138.","journal-title":"J Infect Dis"},{"issue":"2","key":"5115_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"5115_CR45","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1016\/j.vaccine.2018.10.047","volume":"36","author":"S Desai","year":"2018","unstructured":"Desai S, Schanzer DL, Silva A, Rotondo J, Squires SG. Trends in Canadian infant pertussis hospitalizations in the pre- and post-acellular vaccine era, 1981-2016. Vaccine. 2018;36(49):7568\u201373.","journal-title":"Vaccine."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-020-05115-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T23:42:00Z","timestamp":1666309320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-020-05115-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5115"],"URL":"https:\/\/doi.org\/10.1186\/s12913-020-05115-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable; study did not involve human participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All author approved the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HD, FPA and JGLY are employees of Sanofi. The authors declare that they have no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}